Quarterly report · Q3

Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥523.5bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥178.8bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥94.5bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥28.6bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥93.0bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥27.8bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥71.7bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥21.7bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥71.7bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥21.7bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥1.54Tat 2022-12-31Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.40Tat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥469.8bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥935.9bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥935.9bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥204.9bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥98.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥59.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥39.3bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥94.822021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.72021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥94.762021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.692021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-12-31¥190m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥1.7bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥90.2bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥17.2bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥294.4bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥72.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-12-31¥138.7bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-12-31¥19.3bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥523.3bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥108.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 648
ItemContextValueUnit
Finance costs IFRSCurrentQuarterDuration1487000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1QuarterDuration106000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentQuarterDuration440000000JPY
Profit loss before tax IFRSPrior1QuarterDuration27762000000JPY
Profit loss before tax IFRSCurrentQuarterDuration37475000000JPY
Income tax expense IFRSPrior1QuarterDuration6054000000JPY
Income tax expense IFRSCurrentQuarterDuration7616000000JPY
Profit loss IFRSPrior1QuarterDuration21708000000JPY
Profit loss IFRSCurrentQuarterDuration29859000000JPY
Profit loss attributable to owners of parent IFRSPrior1QuarterDuration21708000000JPY
Profit loss attributable to owners of parent IFRSCurrentQuarterDuration29859000000JPY
Profit loss IFRSPrior1QuarterDuration21708000000JPY
Profit loss IFRSCurrentQuarterDuration29859000000JPY
Basic earnings loss per share IFRSPrior1QuarterDuration28.70
Basic earnings loss per share IFRSCurrentQuarterDuration39.97
Diluted earnings loss per share IFRSPrior1QuarterDuration28.69
Diluted earnings loss per share IFRSCurrentQuarterDuration39.96
Profit loss IFRSPrior1YTDDuration71696000000JPY
Profit loss IFRSCurrentYTDDuration70180000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration106000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration1982000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration15000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration864000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1YTDDuration121000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentYTDDuration2847000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration30018000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration65723000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration228000000JPY
Effective portion of cash flow hedges net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration734000000JPY
Cost of hedging net of tax items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration-20000000JPY
Cost of hedging net of tax items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration-341000000JPY
Total of items that may be reclassified to profit or loss oci IFRSPrior1YTDDuration30227000000JPY
Total of items that may be reclassified to profit or loss oci IFRSCurrentYTDDuration66117000000JPY
Other comprehensive income IFRSPrior1YTDDuration30348000000JPY
Other comprehensive income IFRSCurrentYTDDuration68964000000JPY
Comprehensive income IFRSPrior1YTDDuration102045000000JPY
Comprehensive income IFRSCurrentYTDDuration139144000000JPY
Comprehensive income attributable to owners of parent IFRSPrior1YTDDuration102045000000JPY
Comprehensive income attributable to owners of parent IFRSCurrentYTDDuration139144000000JPY
Comprehensive income IFRSPrior1YTDDuration102045000000JPY
Comprehensive income IFRSCurrentYTDDuration139144000000JPY
Profit loss IFRSPrior1QuarterDuration21708000000JPY
Profit loss IFRSCurrentQuarterDuration29859000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-158000000JPY
Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration93000000JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration0JPY
Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration-54000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSPrior1QuarterDuration-158000000JPY
Total of items that will not be reclassified to profit or loss oci IFRSCurrentQuarterDuration39000000JPY
Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRSPrior1QuarterDuration22283000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass